Research programme: intra-neuronal antibody - CytoDel
Latest Information Update: 28 Feb 2025
At a glance
- Originator CytoDel; NYU Grossman School of Medicine
- Class Analgesics; Immunoglobulins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders; Pain
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for research development in Neurological-disorders in USA (Parenteral)
- 28 Feb 2025 No recent reports of development identified for research development in Pain in USA (Parenteral)
- 07 Jan 2021 CytoDel has patent protection for intra-neuronal antibody in USA (CytoDel website, January 2021)